Bempedoic Acid Cuts CV Events in Statin-Intolerant Patients

Bempedoic acid an ‘effective alternative’ for statin-intolerant patients: CLEAR Outcomes

NEW ORLEANS — In the CLEAR Outcomes trial, bempedoic acid reduced risk for major CV events by 13% compared with placebo, including a 23% lower risk for MI, among adults with a history of CVD or at high risk deemed statin intolerant.Bempedoic acid (Nexletol, Esperion Therapeutics) was FDA approved in 2020 for lowering LDL, but the effects of the drug on CV outcomes have not been assessed,

Bempedoic Acid Cuts CV Events in Statin-Intolerant Patients

The CLEAR Outcomes trial establishes this new drug as an important addition to available nonstatin LDL-lowering therapies, experts say.